期刊文献+

MMP-7和HGF在白血病中的表达及其相关性研究 被引量:5

Expression of HGF and MMP-7 in Leukemia
暂未订购
导出
摘要 目的:探讨基质金属蛋白酶-7(MMP-7)和肝细胞生长因子(HGF)在白血病患者中的表达及两者的相关性。方法:采用酶联免疫法(ELISA)检测了50例白血病患者和40例健康对照组外周血中MMP-7和HGF的表达。及经两个疗程标准化疗后50例白血病患者中HGF及MMP-7的表达。结果:HGF和MMP-7在白血病组的表达水平高于对照组,且差异有显著性(P均<0.05),两者之间呈正相关性(r=0.303,P<0.05)。HGF与MMP-7在白血病各分型中的表达无差异(P>0.05),初治组与复发组之间HGF与MMP-7的表达差异无统计学意义(P>0.05)。HGF与MMP-7在白血病完全缓解组(CR)的表达水平明显低于未完全缓解组(PR)(P<0.05)。结论:HGF与MMP-7的高表达可能与白血病的发生发展发病相关。HGF和MMP-7在白血病的早期诊断与治疗中也起到了重要的作用。 Objective: To investigate the expression of MMP-7 and HGF in leukemia and the relationship between the expression and leukemia in the peripheral blood of leukemia. Methods:The expression of MMP-7 and HGF was detected in 50 cases of leukemia and 40 healthy controls by enzyme league immune method (ELISA), and the same to the expression after two courses of chemotherapy. Results:The levels of MMP-7 and HGF in peripheral blood in leukemia were higher than those in healthy adults (P 〈 0.05), with a significant difference (P〈 0.05) and a positive correlation (r = 0. 303,P 〈 0.05) between the MMP--7 expression and the HGF expression. There was no difference in the different types of leukemia between the HGF expres- sion and the MMP--7 expression (P 〉 0.05) as well as no difference in the HGF and the MMP--7 expression between the untreated group and the recurrent group (P 〉 0.05). The expression levels of MMP--7 and HGF in the CR group was lower than those in the PR group, with a significant difference (P 〈 0.05). Conclusion : Higher expression levels of HGF and MMP--7 may play an important role in the peripheral blood in leukemia. Combined analyses of the expression of HGF and MMP--7 may be useful in evaluating the prognosis and treatment of leukemia.
出处 《黑龙江医药科学》 2011年第6期36-37,共2页 Heilongjiang Medicine and Pharmacy
  • 相关文献

参考文献9

  • 1马骊,王小宁.肝细胞生长因子的基础和临床研究进展[J].中国生物制品学杂志,1996,9(3):139-142. 被引量:12
  • 2Liotta LA,Steeg PA,Stetler SWG, Cancer metastasis and angio genesis: an imbalanee of Positive and negative regulation[J]. Cell, 1991,64,327-331.
  • 3Hiroy Uki, ramamoto, Fumio Itoh, et aL Expression of matrix metal- lo Pro--teinases and tissue in hibitors of metaHo Priteinase in human Panereatie adeno--eareinomaelini Pathologie and Pragnostie signi- fieanee of matrilysin expression[J]. Clinoncol,2001,19,1118-1127.
  • 4肖秀英,周晓燕,孙孟红,杜祥.MMP-2和C-erbB-2在散发性结直肠癌原发及转移灶中表达及意义[J].中国癌症杂志,2006,16(1):1-4. 被引量:7
  • 5Bueso--Ramcs CE, Roeha FC, Shishodia S,et al. Expression of consti--tutively active nuclear--kappa B Rel A transcription factor in blasts of acute myeloid leukemia[J]. Hum Pathol, 2004,35:246 -253.
  • 6Wilson CL,Heppner KJ,Labosky PA,et al. Hitestinal tumorigene- sis is suppressed in mice lacking the metal--loproteinase matrilysin [J]. Proc Natl Acad Sci USA,1997,94:1402-1407.
  • 7Nakopoulou L, KatsarouS, Giannopou,et al. Correlation of tissue in hibitor of metalloprotein ase with proliferative activity and patients survival in breast cancer[J ]. Mod Pathol, 2002,15 : 26-34.
  • 8Pepper MS,Matsumoto K. Hepatocyte growth factor increase uro- hinase--type plasmiongen activator and U--PA receptor expression in Madin--Darly canine kidney epithelial eeU[J].Biolchem, 1992, 267(28) : 20493-20499.
  • 9Morishita R,Aoki M, Hashiya N. Hepatocyte growth factor (HGF) angio genic gene therapy: promise for cardiovascular disease[j].Gene Therapy,2002,1(4):343-349.

二级参考文献13

  • 1Streekfus C,Bigler L. The use of soluble, salivary, e-erbB-2 for the detection anti post-operative follow-up of breast cancer in women:the results of a flve-year translational reseamh study [ J ]. Adv Dent Res,2005,18(1 ) :17-24.
  • 2Delektorskaia VV, Perevoshchikov AG, Kushlinskii NE. Expression of nnr23 and c-erbB-2 proteins in cells of primary colorectal cancer and its metastases [ J ]. Arkh Patol, 2003,65 ( 5 ) : 11 - 15.
  • 3Curran S, Dundas SR, Buxton J, et al. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis eolorectal cancers [ J ]. Clin Cancer Res,2004,10( 24 ) :8229-8234.
  • 4Roeb E,Matern S. Matrix metalloproteinases and eolorectal cancer[J].Med Kliln(Munich) ,2003,98(12) :763-770.
  • 5Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in eolorectal cancer progression and metastasis[ J]. Biochim Biophys Acta ,2004,1705 (2) : 69-89.
  • 6Koyama S. Enhanced cell surface expression of matrix metalloproteinases,and their inhibitors, and tumor-induced host response in progression of haman gastric carcinoma[ J]. Dig Dis Sci,2004,49(10) :1621-1630.
  • 7Murray GI. Matrix metalloproteinases: a muhifunctional group of molecules [ J ]. J Ptahol,2001,195 ( 2 ) : 135-137.
  • 8Essapen S, Thomas H, Green M,et al. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters [ J ]. Int J Onco1,2004,24(2) :241-248.
  • 9Half E, Broaddus R, Danenberg KD, et al. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors [ J ]. Int J Cancer, 2004,108 ( 4 ) : 540-548.
  • 10Baselga J, Clinical trials of HERceptin [ J ]. Eur J Cancer,2001,37( suppl 1 ) :18-24.

共引文献17

同被引文献53

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部